CRISM Therapeutics Corporation

CRTX

VGG042401262

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:22 28/06/2024 pm IST			5-day change	1st Jan Change
5.25 ^GBX	0.00%		0.00%	-63.54%

31/05	Crism has first day of trade on AIM after name change, buy	AN
29/05	Amur Minerals confirms Extruded buy, name change and board shake-up	AN

Crism has first day of trade on AIM after name change, buy

May 01, 2024 at 02:31 am IST

Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Begins first day of trading on AIM. On Wednesday, Crism changed its name from Amur Minerals Corp, after purchasing Extruded Pharmaceuticals Ltd and exiting its mineral exploration business.

The company, now Crism, has created ChemoSeed, an innovate polymeric delivery system for chemotherapy. It expects to begin its first clinical trial in 2025. The company says Chemoseed's potential for quick progression to clinical trials would reduce development costs by EUR400,000.

Crism Chief Operating Officer Andrew Webb commented: "We believe Crism has an attractive risk profile owing to using an existing pre-approved drug, irinotecan, and we have a clear strategy for progressing ChemoSeed through development and to commercialisation."

By Aidan Lane, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about CRISM Therapeutics Corporation

Crism has first day of trade on AIM after name change, buy	01/06	AN
Amur Minerals confirms Extruded buy, name change and board shake-up	29/05	AN
Amur Minerals agrees reverse takeover of Extruded Pharma	13/05	AN
Amur Minerals Signs Reverse Takeover Deal With Extruded Pharmaceuticals	13/05	MT
Amur Minerals Corporation executed a share and purchase agreement to acquire Extruded Pharmaceuticals Ltd for £5.5 million.	13/05	CI
Amur Minerals swings to profit in 2023 as costs fall	10/05	AN
Amur Minerals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	10/05	CI
EARNINGS AND TRADING: Impairment charge pushes Quartix into the red	04/03	AN
Amur Minerals Advances Reverse Takeover Deal	04/03	MT
Amur Minerals reports widened interim loss as reviews opportunities	25/23/25	AN
Amur Minerals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Amur Minerals Corporation Announces Special Dividend	25/23/25	CI
Tintra receives bid approach; NCC trading in line	08/23/08	AN
FTSE 100 Closes Up 0.21% on Pound Weakness	07/23/07	DJ
UK Inflation Expectations Fall, Boosting Prospects for BOE Rate Pause	07/23/07	DJ
UK Gilt Yields Fall on Rising Expectations of a BOE Rate Pause	07/23/07	DJ
FTSE 100 Falls After Weak Performance in Asian Markets	07/23/07	DJ
Amur Minerals Shares Cease Trading on London Bourse's AIM Submarket	07/23/07	MT
Amur Minerals Notes AIM’s Reverse Takeover Requirement	15/23/15	MT
FTSE 100 Closes Down as Investors Driven into Risk-Off Mood	08/23/08	DJ
Sterling Likely to Fall in Longer Run as Markets Overestimate Rate Prospects	08/23/08	DJ
Amur Minerals ends discussions over possible Ascent Resources takeover	08/23/08	AN
FTSE 100 Edges Lower as Miners Fall After Weak China Trade Data, Glencore Earnings	08/23/08	DJ
Glencore's Results Could Lead to Consensus Cuts	08/23/08	DJ
Amur Minerals Ends Merger Talks with Ascent Resources	08/23/08	MT

Chart CRISM Therapeutics Corporation

Duration

Period

More charts

Company Profile

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

Sector

Pharmaceuticals

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRISM THERAPEUTICS CORPORATION	-63.54%	6L
ELI LILLY AND COMPANY	+55.32%	82TCr
NOVO NORDISK A/S	+44.05%	64TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr